Sam Chun Dang Pharm. Co., Ltd

000250.KQ

000250.KQSam Chun Dang Pharm. Co., Ltd KR flag

KOSDAQ

146,200.00

KRW

+8,000.00

(+5.79%)

3.17TMarket Cap

Nov 12Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7000250001

Return %

Stock

S&P500

92.62

32.83

236.09

33.33

320.11

95.62

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	4,018.94	3,945.7	5,416.69	5,972.37	6,473.55	7,138.85	7,506.74	7,473.18	8,712.66	7,775.69	7,578.07	8,050.31	8,591.73	9,106.72
Basic EPS, GAAP	293.49	69	452	595	570	422	585	409	488	-45	-750	265	-463	-249.27
Free Cash Flow per Basic Share	467.64	-93.53	582.64	442.67	312.12	419.24	806.56	237.03	954.54	-398.32	-1,676.83	-1,510.18	64.87	502.27
Dividend per Share	100	49.68	50	48.46	122.51	98.02	96.38	96.57	96.51	96.32	43.87	43.96	39.28	- -
Book Value per Share	3,820.83	3,821.33	4,235.73	4,586.29	4,887.73	5,240.07	5,475.47	6,000.53	6,402.42	6,448.01	5,612.97	5,604.7	5,250.6	- -
Tangible Book Value per Share	4,272.98	4,181.51	5,910.31	6,669.52	7,144.41	7,650.56	8,354.41	8,629.27	9,010.04	10,476.79	9,238.17	7,481.32	9,014.96	15,892.41
Basic Weighted Avg Shares	19	19	19	20	20	21	21	21	21	21	22	22	22	22
Sales/Revenue/Turnover	77,566	76,650	104,543	118,924	132,062	147,373	160,587	159,960	186,602	166,862	167,275	177,335	192,669	204,281
Operating Margin (%)	9.07	7.77	15.19	15.93	15.72	16.53	14.93	9.69	13.51	3.31	-9.14	6.89	4.96	15.69
Depreciation Expense	1,922	2,319	4,112	4,082	4,220	5,358	6,250	6,303	6,491	6,685	6,741	7,651	8,430	6,172
Net Income, GAAP	5,664	1,340	8,724	11,848	11,628	8,712	12,515	8,754	10,452	-966	-16,555	5,838	-10,383	-5,592
Effective Tax Rate (%)	23.98	77.76	21	13.71	14.22	31.08	14.92	- -	- -	54.8	- -	0.98	- -	69.91
Profit Margin (%)	7.3	1.75	8.34	9.96	8.81	5.91	7.79	5.47	5.6	-0.58	-9.9	3.29	-5.39	-2.74
Working Capital	51,891	32,342	56,968	67,624	77,232	90,457	107,508	103,853	117,287	142,869	114,901	119,590	105,949	171,319
LT Debt	- -	6,441	1,374	- -	- -	- -	3,000	7,177	9,573	24,149	29,248	72,505	19,929	- -
Total Equity	84,092	86,634	119,231	139,676	154,315	171,003	193,756	205,763	223,197	257,696	250,301	245,642	298,460	356,497
Return on Invested Capital (%)	6.45	1.41	10.41	11.59	11.72	9.93	10.76	- -	- -	0.93	- -	3.88	- -	2.72
Return on Capital (%)	7.91	1.58	9.55	5.37	4	1.24	2.81	- -	- -	-3.95	- -	2.14	- -	-6.26
Return on Common Equity (%)	7.94	1.81	11.19	13.69	12.17	8.38	11.11	7.13	7.87	-0.7	-12.62	4.72	-8.61	-8.98

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	6.6%	4.2%	8.65%
Net Income, GAAP	113.39%	222.28%	-277.86%
Free Cash Flow	39.5%	75.94%	-104.37%
Total Cash Common Dividend	- -	- -	-9.04%
Total Equity	9.86%	8.14%	21.5%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Chun In Seok
Full Time Employees: 375
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Address: South Korea
IPO Date: Sep 11, 2001
Website: scd.co.kr
Similar Companies: Café Serendipity Holdings, Inc. (CAFS)
Trinity League India Limited (TRINITYLEA.BO)
Evoq Remedies Limited (EVOQ.BO)
Vikram Thermo (India) Limited (VIKRAMTH.BO)
ST Pharm Co.,Ltd. (237690.KQ)
Aclaris Therapeutics, Inc. (0H8T.L)
Business: SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. Its products include antibiotics, cures for the circulatory and respiratory system, medicines for the digestive system and ophthalmology, and anti-inflammatory. The company was founded on December 29, 1943 and is headquartered in Hwaseong-si, South Korea.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	4,018.94	3,945.7	5,416.69	5,972.37	6,473.55	7,138.85	7,506.74	7,473.18	8,712.66	7,775.69	7,578.07	8,050.31	8,591.73	9,106.72
Basic EPS, GAAP	293.49	69	452	595	570	422	585	409	488	-45	-750	265	-463	-249.27
Free Cash Flow per Basic Share	467.64	-93.53	582.64	442.67	312.12	419.24	806.56	237.03	954.54	-398.32	-1,676.83	-1,510.18	64.87	502.27
Dividend per Share	100	49.68	50	48.46	122.51	98.02	96.38	96.57	96.51	96.32	43.87	43.96	39.28	- -
Book Value per Share	3,820.83	3,821.33	4,235.73	4,586.29	4,887.73	5,240.07	5,475.47	6,000.53	6,402.42	6,448.01	5,612.97	5,604.7	5,250.6	- -
Tangible Book Value per Share	4,272.98	4,181.51	5,910.31	6,669.52	7,144.41	7,650.56	8,354.41	8,629.27	9,010.04	10,476.79	9,238.17	7,481.32	9,014.96	15,892.41
Basic Weighted Avg Shares	19	19	19	20	20	21	21	21	21	21	22	22	22	22
Sales/Revenue/Turnover	77,566	76,650	104,543	118,924	132,062	147,373	160,587	159,960	186,602	166,862	167,275	177,335	192,669	204,281
Operating Margin (%)	9.07	7.77	15.19	15.93	15.72	16.53	14.93	9.69	13.51	3.31	-9.14	6.89	4.96	15.69
Depreciation Expense	1,922	2,319	4,112	4,082	4,220	5,358	6,250	6,303	6,491	6,685	6,741	7,651	8,430	6,172
Net Income, GAAP	5,664	1,340	8,724	11,848	11,628	8,712	12,515	8,754	10,452	-966	-16,555	5,838	-10,383	-5,592
Effective Tax Rate (%)	23.98	77.76	21	13.71	14.22	31.08	14.92	- -	- -	54.8	- -	0.98	- -	69.91
Profit Margin (%)	7.3	1.75	8.34	9.96	8.81	5.91	7.79	5.47	5.6	-0.58	-9.9	3.29	-5.39	-2.74
Working Capital	51,891	32,342	56,968	67,624	77,232	90,457	107,508	103,853	117,287	142,869	114,901	119,590	105,949	171,319
LT Debt	- -	6,441	1,374	- -	- -	- -	3,000	7,177	9,573	24,149	29,248	72,505	19,929	- -
Total Equity	84,092	86,634	119,231	139,676	154,315	171,003	193,756	205,763	223,197	257,696	250,301	245,642	298,460	356,497
Return on Invested Capital (%)	6.45	1.41	10.41	11.59	11.72	9.93	10.76	- -	- -	0.93	- -	3.88	- -	2.72
Return on Capital (%)	7.91	1.58	9.55	5.37	4	1.24	2.81	- -	- -	-3.95	- -	2.14	- -	-6.26
Return on Common Equity (%)	7.94	1.81	11.19	13.69	12.17	8.38	11.11	7.13	7.87	-0.7	-12.62	4.72	-8.61	-8.98

	Dec'23	Mar'24	Jun'24
Total Current Assets	163,906	164,493	245,544
Accounts Receivable, Net	30,426	32,019	- -
Cash, Cash Equivalents & STI	92,744	84,641	- -
Inventories	35,263	38,772	- -
Total Current Liabilities	57,957	61,140	74,225
Payables & Accruals	- -	- -	- -
ST Debt	33,696	33,854	- -
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	33,696	33,854	- -
LT Borrowings	16,000	16,000	- -
LT Finance Leases	3,929	3,605	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	23	23	23
Market Capitalization	1,711,121	3,136,873	3,277,301

Year	Q1	Q2	Q3	Q4	FY
2022	41,818	47,182	43,831	44,504	177,335
2023	44,155	47,579	48,443	52,491	192,669
2024	48,457	54,890	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	135.79	-92.02	- -	- -	43.96
2023	- -	- -	- -	- -	39.28
2024	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	83	50	120	- -	265
2023	16	-173.72	-535.3	- -	-463
2024	50	- -	- -	- -	- -

Sam Chun Dang Pharm. Co., Ltd

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year